Associated Papers
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Gene polymorphisms of ABC transporters are associated with clinical outcomes in children with acute lymphoblastic leukemia.
Zhai X et al.
Archives of Medical Science : Ams, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K et al.
Advanced Drug Delivery Reviews, 2009
The identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional protein.
Yoshioka S et al.
Pharmaceutical Research, 2007
Low penetrance genetic susceptibility to kidney cancer.
Thibault F et al.
Bju International, 2006
Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development.
Yanase K et al.
Cancer Letters, 2006
Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
Mizuarai S et al.
International Journal of Cancer, 2004
Select a paper to view details